Free tool
FAERS Monitor: Vimpat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022255 or its brand name (Vimpat, Lacosamide). Reports on generic versions are filed under their own applications.
Reports
37,919
Serious
29,864
79% of reports
Hospitalization
13,001
Death reported
3,199
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure6,979
- drug ineffective4,243
- off label use4,083
- dizziness1,693
- somnolence1,521
- fatigue1,474
- epilepsy1,466
- fall1,436
- overdose1,308
- status epilepticus1,291
- generalised tonic-clonic seizure1,209
- death1,095
- headache1,082
- drug interaction1,026
- nausea967
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 332 |
| 2010 | 611 |
| 2011 | 886 |
| 2012 | 875 |
| 2013 | 929 |
| 2014 | 956 |
| 2015 | 1,994 |
| 2016 | 1,342 |
| 2017 | 1,652 |
| 2018 | 2,469 |
| 2019 | 3,766 |
| 2020 | 2,936 |
| 2021 | 3,545 |
| 2022 | 3,208 |
| 2023 | 3,140 |
| 2024 | 3,497 |
| 2025 | 3,315 |
| 2026 | 2,463 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,240 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| status epilepticusSignal | 1,291 | 71.5 | 67.5 | 79,442 |
| generalised tonic-clonic seizureSignal | 1,209 | 43.6 | 41.2 | 46,687 |
| seizureSignal | 6,979 | 35.6 | 34.8 | 221,729 |
| epilepsySignal | 1,466 | 27.9 | 26.5 | 36,207 |
| somnolenceSignal | 1,521 | 4.2 | 4.0 | 3,733 |
| drug interactionSignal | 1,026 | 3.6 | 3.4 | 1,930 |
| overdoseSignal | 1,308 | 3.4 | 3.2 | 2,196 |
| off label useSignal | 4,083 | 2.6 | 2.5 | 4,151 |
| fallSignal | 1,436 | 2.4 | 2.3 | 1,184 |
| dizziness | 1,693 | 1.9 | 1.8 | 718 |
| drug ineffective | 4,243 | 1.8 | 1.7 | 1,567 |
| fatigue | 1,474 | 1.1 | 1.0 | 4 |
| headache | 1,082 | 1.0 | 0.9 | 2 |
| death | 1,095 | 0.7 | 0.7 | 141 |
| nausea | 967 | 0.7 | 0.6 | 154 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.